BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance

Stock Information for Valeo Pharma Inc - Ordinary Shares

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Valeo Pharma Inc - Ordinary Shares

BDSI Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of BioDelivery Sciences International to Collegium Pharmaceutical
Collegium to Acquire BioDelivery Sciences in an All-Cash Deal
BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032
BioDelivery Sciences Reports Solid Third Quarter 2021 Results
BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer
BioDelivery Sciences to Report Third Quarter 2021 Financial Results on November 3, 2021
BioDelivery Sciences International to Host ELYXYB(TM) Investor Day
BioDelivery Sciences International Completes Acquisition of ELYXYB(TM) for Acute Migraine Treatment in the U.S. and Canada

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.